USCOM LIMITED — Regulatory Filings 2017

May 23, 2017

ASX MEDIA RELEASE

Uscom SpiroSonic Devices for French Lung Transplant Study

SYDNEY, Australia, Wednesday 24[th] May 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) announced a partnership with French Company Aqsitania SAS to use the new Uscom SpiroSonic tSpiro telemetric pulmonary function devices for the monitoring and improved management of lung transplant patients. The tSpiro devices are advanced multi-path ultrasonic spirometers that connect wirelessly to personal communication devices, and ultimately web based software applications to monitor and analyse respiratory function allowing cost effective home care monitoring.

Key Points

• Lung transplantation is expensive and requires on going pulmonary functional monitoring

• Uscom tSpiro multi-path ultrasonic spirometers provide practice leading pulmonary function measurements

• Uscom digital connectivity allows for home care monitoring of lung transplantation patients

• • Aqsitania SAS is a French Company specialising in eHealth applications of advanced signal analysis and modelling particularly of respiratory function and development of Personal Respiratory Profiles (PRPs)

• Aqsitania have purchased approximately 100 Uscom tSpiro devices for the pilot project, with further orders for several hundred devices anticipated for the second phase of the project

• The Uscom tSpiro platform of devices are currently under consideration for use by a number of digital telemetric asthma and COPD solution companies around the world developing cloud based monitoring and diagnosis software and analytics models

• tSpiro devices are approved for European sales, and are currently being submitted for US FDA and Chinese CFDA approval.

• The Aqsitania SAS Lung Transplantation project is supported by European Union funding.

Uscom’s Global Head of Digital Pulmonary Devices, George Ferenczi said, “Our new SpiroSonic tSpiro devices deliver research quality digital ultrasonic telemetric spirometry into the home care market, allowing specialist monitoring of pulmonary function in the patient’s home, providing more effective management and reducing expensive hospital attendances. Application of tSpiro for monitoring and guiding management of lung transplantation patients is new, and expands our established application in Asthma, COPD and Occupation Lung Disease.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Digital telemetric spirometry is the future of pulmonary medicine and we are at the forefront of this field. Aqsitania SAS is a world leader in pulmonary function signal analysis, and their algorithms depend on the highest quality spirometry sensors. We are delighted they are using Uscom tSpiro devices for their program to improve the care of lung transplants patients. We are already leaders in digital cloud based home care for asthma and COPD and Occupational Lung Disease Monitoring, and this is a further clinical application for our new SpiroSonic devices.”

Digital cloud based pulmonary monitoring is an emerging global trend in clinical care, and provides for early detection of changes in pulmonary function and improved guidance of therapy. This collaboration between Aqsitania SAS and Uscom Europe is supported by European Union funding is recognition of the superior quality of the SpiroSonic digital spirometers.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.

References: http://www.aqsitania.com

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specializing in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced hemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Pediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and pediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze pulse pressure waves and generate a summary report.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialized for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand-alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyze spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7 10 Loftus Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au